Boston Scientific (BSX) has agreed to make an undisclosed, one-time payment to OrbusNeich to settle all stent-based litigation. This includes settling lawsuits in the United States, the Netherlands, Ireland, Germany and the UK. OrbusNeich is a vascular medical devices company with headquarters in Hong Kong and U.S. offices in Ft. Lauderdale, Fla. In May, OrbusNeich […]
The standard of care for port site closures in laparoscopic surgery may be changing. Irish medical device startup neoSurgical‘s first commercialized product, neoClose, officially launched this week in the U.S. Today, the Society of Laparoendoscopic Surgeons named the device one of the 2013 Innovations of the Year at the SLS Minimally Invasive Surgery Week Annual Meeting. […]
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Boston Scientific (BSX) announced it has received U.S. Food and Drug Administration approval for its IntellaTip MiFi XP catheter and 501(k) clearance for its Zurpaz 8.5F steerable sheath, growing its EP mapping/ablation technology portfolio. This makes it the third major player–following both St. Jude Medical, which acquired Endosense, and GE, which invested in Acutus Medical–to […]
CVRx, a Minneapolis-based firm that has developed proprietary implantable technology for the treatment of high blood pressure and heart failure, has raised $29.6 million for advancing clinical trials of its Barostim Neo, as well as expanding commercial activities abroad. Johnson & Johnson Development Corp. and New Enterprise Associates, Inc. were the co-lead investors. According to […]
In announcing its fourth-quarter earnings Tuesday, Boston Scientific (NYSE:BSX) also announced that it was reducing its workforce by 900 to 1,000 people worldwide, a move that will lower pre-tax operating expenses by $100 million to $115 million by the end of the year. The reduction will occur through a mixture of attrition and layoffs. A […]
It’s not great when a company needs a rival to have a major disaster in order to see the upside, but when you are Boston Scientific (NYSE: BSX), it may be welcome news indeed. That is the queer situation Boston Scientific finds itself in at the close of a tough year. Or at least that […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
UPDATED WITH ANALYST COMMENT Boston Scientific (NYSE:BSX) is jumping on the renal denervation bandwagon. The Natick, Massachusetts, medical device manufacturer announced Thursday that it is buying Caifornia startup Vessix Vascular for an upfront payment of $125 million and the prospect of additional milestone payments between 2013 and 2019 that would make the transaction be […]
Earlier on Monday, Boston Scientific (NYSE:BSX) announced that it is acquiring Rhythmia Medical, which makes 3D navigational software in cardiac procedures to treat variety of conditions including irregular heart beat for an up front $90 million. Boston Scientific will pay an additional $175 million provided the Burlington, Massachusetts, firm’s technology wins regulatory clearance as well […]
On Wednesday, after Boston Scientific (NYSE:BSX) announced the acquisition of Minnesota startup BridgePoint Medical, the startup’s CEO said that he is excited by the prospect of having the company’s technology marketed by Boston Scientific’s sales and marketing operation. Describing Boston Scientific as the “leader” in the interventional cardiology field and the cath lab, Denis Harrington […]
Boston Scientific (NYSE:BSX) announced Wednesday that it is acquiring Minneapolis-based BridgePoint Medical, which has developed minimally invasive technologies to treat complete blockage of the coronary artery or coronary chronic total occlusions. The terms of the transaction, expected to close in the fourth quarter, were not disclosed. BridgePoint Medical’s Coronary Total Occlusion (CTO) system comprises the CrossBoss CTO […]
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
If Boston Scientific (NYSE: BSX) were to break up its cardiac rhythm management business into a cardiac unit and an interventional cardiology unit as Reuters reported, the move will spell the recognition that an integrated sales force could not bring about lowered selling costs without an accompanying loss in revenue. That is the opinion of […]
For the last year, Boston Scientific’s (NYSE:BSX) stock has hovered between $5 and $6, and no amount of share buybacks have nudged the price up much. In the company’s second-quarter earnings call last week, analyst Michael Weinstein of JP Morgan asked chief financial officer Jeffrey Capello whether repurchasing shares was the best use of Boston Scientific’s […]
If people are looking for confirmation that the global cardiac rhythm management market has declined as much as it could and will fall no further, they have to wait a while. A week ago St. Jude Medical CEO Dan Starks admitted that the company has been routinely too optimistic in predicting the bottom of the […]
Neurostimulation device company Neuros Medical Inc. has landed $3.5 million in its second round of funding from a handful of investors including medical device powerhouse Boston Scientific (NYSE:BSX). The company’s device, called the Electrical Nerve Block, comprises a pacemaker-sized generator and a lead that wraps around a peripheral nerve, and delivers stimulation to block pain. […]
Boston Scientific announced Monday that it is collaborating with Royal Philips Electronics through which the Dutch company will sell Boston Scientific Imaging equipment compatible with its imaging systems globally. Specifically, the marketing and distribution agreement relates to Boston Scientific’s iLabs ultrasound imaging system and its imaging catheters, which will now be sold with Philips’ Allura Xper […]